Literature DB >> 16741620

Therapeutic benefit of sulfasalazine for patients with primary sclerosing cholangitis.

Shinichiro Tada, Hirotoshi Ebinuma, Hidetsugu Saito, Toshifumi Hibi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16741620     DOI： 10.1007/s00535-005-1758-x

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN： 0944-1174            Impact factor:   7.527


× No keyword cloud information.
  6 in total

1.  The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.

Authors:  M A Peppercorn; P Goldman
Journal:  J Pharmacol Exp Ther       Date:  1972-06       Impact factor: 4.030

2.  Three paediatric cases of primary sclerosing cholangitis treated with ursodeoxycholic acid and sulphasalazine.

Authors:  K Kozaiwa; H Tajiri; A Sawada; K Tada; Y Etani; K Miki; S Okada
Journal:  J Gastroenterol Hepatol       Date:  1998-08       Impact factor: 4.029

Review 3.  Glucocorticosteroids for primary sclerosing cholangitis.

Authors:  W Chen; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2004

4.  5-Aminosalicylic acid abrogates T-cell proliferation by blocking interleukin-2 production in peripheral blood mononuclear cells.

Authors:  C Stevens; M Lipman; S Fabry; M Moscovitch-Lopatin; W Almawi; S Keresztes; M A Peppercorn; T B Strom
Journal:  J Pharmacol Exp Ther       Date:  1995-01       Impact factor: 4.030

Review 5.  Bile acids for primary sclerosing cholangitis.

Authors:  W Chen; C Gluud
Journal:  Cochrane Database Syst Rev       Date:  2003

6.  Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.

Authors:  I Ahnfelt-Rønne; O H Nielsen; A Christensen; E Langholz; V Binder; P Riis
Journal:  Gastroenterology       Date:  1990-05       Impact factor: 22.682
  6 in total
  5 in total

Review 1.  Pharmacological interventions for primary sclerosing cholangitis: an attempted network meta-analysis.

Authors:  Francesca Saffioti; Kurinchi Selvan Gurusamy; Neil Hawkins; Clare D Toon; Emmanuel Tsochatzis; Brian R Davidson; Douglas Thorburn
Journal:  Cochrane Database Syst Rev       Date:  2017-03-28

Review 2.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

Review 3.  The medical management of primary sclerosing cholangitis.

Authors:  Anthony Michaels; Cynthia Levy
Journal:  Medscape J Med       Date:  2008-03-12

Review 4.  Role of the microbiota and antibiotics in primary sclerosing cholangitis.

Authors:  James H Tabibian; Jayant A Talwalkar; Keith D Lindor
Journal:  Biomed Res Int       Date:  2013-10-22       Impact factor: 3.411

5.  Dysbiosis of the salivary microbiota in pediatric-onset primary sclerosing cholangitis and its potential as a biomarker.

Authors:  Kentaro Iwasawa; Wataru Suda; Tomoyuki Tsunoda; Manari Oikawa-Kawamoto; Shuichiro Umetsu; Lena Takayasu; Ayano Inui; Tomoo Fujisawa; Hidetoshi Morita; Tsuyoshi Sogo; Masahira Hattori
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.